InSite ties up with Quest on glaucoma test:
This article was originally published in Clinica
Quest Diagnostics and ophthalmic products company InSite Vision have set up a one-year agreement under which Quest will provide lab services in the US for InSite's OcuGene genetic test for the early prognosis and diagnosis of glaucoma. The OcuGene kit, introduced recently in the US by the Alameda, California company, consists of a pair of buccal brushes used to swab the inside of the patient's cheek. Quest will test the samples for gene mutation at its Nichols Institute site in San Juan Capistrano, California.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.